MINI FUTURE LONG - GILEAD SCIENCES | Delayed Deutsche Boerse AG 19:20:59 20/06/2024 BST | ||
| 1.57 EUR | +46.73% |
|
| Current month | -7.76% | ||
| 1 month | -27.70% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
| Date | Price | Change |
|---|---|---|
| 20/06/24 | 1.57 | +46.73% |
| 19/06/24 | 1.07 | -1.83% |
| 18/06/24 | 1.09 | -11.38% |
| 17/06/24 | 1.23 | -3.91% |
| 14/06/24 | 1.28 | +15.32% |
Delayed Quote Deutsche Boerse AG
Last update June 20, 2024 at 07:20 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
BNP Paribas
|
| WKN | PF3VJ2 |
| ISIN | DE000PF3VJ29 |
| Date issued | 05/11/2020 |
| Strike | 51.42 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.98 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.94 € |
|---|---|
| Lowest since issue | 0.78 € |
| Spread | 0.01 € |
| Spread % | 0.65% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
63.15
USD
Average target price
82.7
USD
Spread / Average Target
+30.95%
- Stock Market
- Certificates
- Certificat
